CHINA ART FIN (01572) announces annual performance, with a net loss of 291,000 yuan attributable to shareholders, turning from a profit to a loss compared to the previous year.
The Chinese Art Finance (01572) released the annual performance as of December 31, 2025, with a revenue of RMB 134 million, an increase of 87.33% year-on-year; the net loss attributable to shareholders was RMB 291,000, a turnaround from profit to loss; loss per share was 0.03 cents.
CHINA ART FIN (01572) announces its full-year performance for the year ending on December 31, 2025, with a revenue of RMB 134 million, an increase of 87.33% year-on-year. Shareholders suffered a net loss of RMB 291,000, turning from profit to loss, with a loss per share of 0.03 cents.
Related Articles
IMMUNOTECH-B (06978) released its annual performance report, with a net loss attributable to shareholders of 231 million yuan, an increase of 23.47% year-on-year.
CHINA POWER (02380) will distribute a final dividend of 0.168 yuan per share on June 30th.
FAMOUS TECH INT (08100) released its financial performance for the year 2025, with a net loss of HK$5,446,000 for shareholders.
IMMUNOTECH-B (06978) released its annual performance report, with a net loss attributable to shareholders of 231 million yuan, an increase of 23.47% year-on-year.
CHINA POWER (02380) will distribute a final dividend of 0.168 yuan per share on June 30th.
FAMOUS TECH INT (08100) released its financial performance for the year 2025, with a net loss of HK$5,446,000 for shareholders.
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
